Researchers tested a low-molecular-weight oat beta-(1,3)(1,4)-glucan in Me45 melanoma and A431 carcinoma cells, alongside normal HaCaT keratinocytes and P388/D1 murine macrophages. Cancer-cell viability decreased with longer exposure and higher concentrations, while the normal-cell model showed less toxicity. Caspase-12 staining increased in the cancer cell lines. These preliminary cell-culture results cannot show that oral oat beta-glucan treats cancer in humans and do not directly apply to Aureobasidium beta-(1,3)(1,6)-glucan.
Low-molecular-weight oat beta-glucan was tested in two cancer cell lines, a normal keratinocyte line, and murine macrophages.
Cancer-cell viability fell with concentration and exposure time, and caspase-12 staining increased in the cancer cells.
This was preliminary in-vitro research on oat glucan. It does not establish cancer treatment effects in humans or equivalence with Aureobasidium glucan.
AI-generated summary for accessibility. Always refer to the original paper.
Choromanska A., Kulbacka J., Rembialkowska N., Pilat J., Harasym J., Rossowska J., Saczko J.. Anticancer properties of low molecular weight oat beta-glucan – An in vitro study. International Journal of Biological Macromolecules. 2015. DOI: 10.1016/j.ijbiomac.2015.05.035.
For scientific reference only. Not medical advice. Consult a qualified healthcare professional. See our Medical Disclaimer.